Brief: Tango Therapeutics Q4 Basic EPS USD -0.32
18/03/2024 11:00
Mar 18 (Reuters) - Tango Therapeutics Q4 operating income USD -35.013 million. * Q4 net income USD -30.763 million * Q4 operating expenses USD 40.444 million
Recent news on Tango Therapeutics
See all newsBrief: Tango Therapeutics, Inc. Approved A Strategic Reprioritization Of The Company’S Research And Development Activities
Brief: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Tango Therapeutics - Files Prospectus To Sell Up To $400 Million In Common Stock
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,